MedPath
HSA Approval

SCMC SYRUP 100 100 mg/5 ml

SIN02852P

SCMC SYRUP 100 100 mg/5 ml

SCMC SYRUP 100 100 mg/5 ml

May 22, 1989

BEACONS PHARMACEUTICALS PTE. LTD.

BEACONS PHARMACEUTICALS PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantBEACONS PHARMACEUTICALS PTE. LTD.
Licence HolderBEACONS PHARMACEUTICALS PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Pharmacy Only
HSA Singapore Classification

Formulation Information

SYRUP

ORAL

Medical Information

R05CB03

carbocisteine

Manufacturer Information

BEACONS PHARMACEUTICALS PTE. LTD.

BEACONS PHARMACEUTICALS PTE LTD

Active Ingredients

CARBOCISTEINE

100 mg/5 ml

Carbocisteine

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SCMC SYRUP 100 100 mg/5 ml - HSA Approval | MedPath